Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, Needham & Company LLC Analyst Says
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target upped by equities research analysts at Needham & Company LLC from $8.00 to $25.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of […]
